Loading clinical trials...
Loading clinical trials...
A Randomized, Two-period, Cross-over, Phase 2 Study, Comparing Pharmacokinetics, and Assessing Safety and Tolerability of Peripheral and Central i.v. Administration of Melphalan Flufenamide (Melflufen) in RRMM Patients
Conditions
Interventions
Melphalan
Dexamethasone
Locations
10
United States
The Oncology Institute of Hope & Innovation - Glendale
Glendale, California, United States
Specialized Hospital for Active Treatment of Hematological Diseases, Sofia
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "Sveta Marina", Varna
Varna, Bulgaria
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology
Brno, Czechia
University Hospital Olomouc, Clinic of Hemato-Oncology
Olomouc, Czechia
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation
Budapest, Hungary
Start Date
August 4, 2020
Primary Completion Date
June 2, 2021
Completion Date
January 10, 2022
Last Updated
March 9, 2023
NCT06285318
NCT05730036
NCT06645678
NCT06961669
NCT07407010
Lead Sponsor
Oncopeptides AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions